Organization
Institut Cancerologie de l'Ouest
18 clinical trials
Clinical trial
Thrombin Generation and Prediction of Thromboembolic Events in Oncology Patients at RiskStatus: Recruiting, Estimated PCD: 2026-09-01
Clinical trial
Pilot Study in Cancer Patients Scheduled for Surgery Evaluating Different Smoking Cessation Protocols : Nicotine Replacement, Motivational Interviewing (MI), Cognitive Behavioural Therapy (CBT) or HypnotherapyStatus: Active (not recruiting), Estimated PCD: 2024-09-01
Clinical trial
Relapse in Previously Irradiated Prostate Bed : a Phase I/II Study of Stereotactic Ablative Reirradiation Potentiated by MetforminStatus: Recruiting, Estimated PCD: 2028-11-01
Clinical trial
Pilot Study of Preservation of Fertility by Ovarian Stimulation Associated With Tamoxifen, and Freezing Oocyte or Embryo Prior Chemotherapy for Breast CancerStatus: Active (not recruiting), Estimated PCD: 2017-07-01
Clinical trial
Multicentric Phase II Trial of Salvage Radiotherapy Combined With Hormonotherapy in Oligometastatic Pelvic Node Relapses of Prostate Cancer (OLIGOPELVIS / GETUG P07)Status: Active (not recruiting), Estimated PCD: 2018-07-24
Clinical trial
OP2C : Prialt® Observatory in Clinical PracticeStatus: Recruiting, Estimated PCD: 2027-01-01
Clinical trial
A Study Comparing Intermittent Androgen Depriving Therapy With Or Without Salvage High-Dose Intensity Modulation Radiotherapy (IG-IMRT)To Oligometastatic Pelvic Lymph Nodes In Biochemically-relapsing Prostate Cancer Patients.Status: Active (not recruiting), Estimated PCD: 2026-06-01
Clinical trial
Phase I Study of Escalated Pharmacologic Dose, of Oral Folinic Acid in Combination With Temozolomide, According to Stupp R. Regimen, in Patients With Operated Grade-IV Astocytoma and a Non-methylated Gene Status of MGMT.Status: Terminated, Estimated PCD: 2019-12-12
Clinical trial
Prediction in Silico of Overall Survival in a Pilot Prospective Cohort Study of Metastatic Breast Cancer PatientsStatus: Recruiting, Estimated PCD: 2035-12-24
Clinical trial
Evaluation of 64Cu-ATSM PET/CT in Predicting Neo Adjuvant Treatment Response in Locally Advanced Rectum CancerStatus: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
Prospective Phase II Pilot Study, Assessing Imaging Performance of 89Zirconium-labelled Girentuximab (89Zr-TLX250) PET-CT (Positron Emission Tomography/Computerized Tomography) in Metastatic Triple Negative Breast Cancer PatientsStatus: Recruiting, Estimated PCD: 2024-03-01
Clinical trial
Pilot Feasibility Study: Inflammation and Presence of M2 Macrophages Explorations With[18F]-DPA-714 PET/CT in Triple Negative Breast CancersStatus: Completed, Estimated PCD: 2021-07-21
Clinical trial
A Pilot Open-label, Feasibility Study to Assess safEty, Tolerability, Radiation Dosimetry, and Imaging Properties of 89Zr-labeled giRenTuximab (89Zr-Girentuximab) in patIents With Non-musclE-iNvasive Bladder CancEr (NMIBC)Status: Completed, Estimated PCD: 2022-08-24
Clinical trial
Local Ablative Stereotactic Radiotherapy for Residual Hypermetabolic Lesion in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Long-term Responders to Immunotherapy : a Randomized, Multicenter, Open-label Phase III StudyStatus: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
Capsaicin 179 mg Patch Versus Oral Duloxetine in Patients With Chemotherapy-induced Peripheral Neuropathy : a Phase 3 Randomized Multicentric Open-label Study.Status: Not yet recruiting, Estimated PCD: 2027-03-01
Clinical trial
Multicentric, Open, Randomized Study Comparing Topical Treatment by Patch of Capsaicin to 8% (Qutenza) to Pregabalin Oral in the Early Treatment of Neuropathic Pain After Primary Surgery for Breast CancerStatus: Completed, Estimated PCD: 2022-11-18
Clinical trial
A Randomized Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) With or Without Durvalumab (MEDI4736) in Oligometastatic Recurrent Hormone Sensitive Prostate Cancer PatientsStatus: Active (not recruiting), Estimated PCD: 2023-12-27
Clinical trial
Corticodependent or Corticoresistant Brain Radionecrosis After Radiotherapy for Brain Metastases: a Multicentre Randomized, Controlled Double-blind Phase III Study, Comparing Bevacizumab Versus PlaceboStatus: Not yet recruiting, Estimated PCD: 2028-03-01